607373-82-0

Basic information

• Product Name: 5-NITRO-2-HYDROXY-4-METHOXYPYRIDINE
• Synonyms: 4-Methoxy-5-nitro-1H-pyridin-2-one;4-Methoxy-5-nitropyridin-2(1H)-one;4-Methoxy-5-nitropyridin-2(1H);2-HYDROXY-4-METHOXY-5-NITROPYRIDINE;5-NITRO-2-HYDROXY-4-METHOXYPYRIDINE;2(1H)-Pyridinone,4-methoxy-5-nitro-(9CI);4-METHOXY-5-NITROPYRIDIN-2-OL;2-Hydroxy-4-methoxy-5-nitropyridine ,98%
• CAS NO: 607373-82-0
• Molecular Formula: C₆H₆N₂O₄
• Molecular Weight: 170.12
• Product Categories: METHOXY;Building Blocks;Pyridine
• Mol File: 607373-82-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 439 °C at 760 mmHg
• Flash Point: 219.3 °C
• Appearance: /
• Density: 1.454 g/cm³
• Vapor Pressure: 2.56E-08mmHg at 25°C
• Refractive Index: 1.589
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Very Slightly)
• PKA: 7.12±0.10(Predicted)
• CAS DataBase Reference: 5-NITRO-2-HYDROXY-4-METHOXYPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-NITRO-2-HYDROXY-4-METHOXYPYRIDINE(607373-82-0)
• EPA Substance Registry System: 5-NITRO-2-HYDROXY-4-METHOXYPYRIDINE(607373-82-0)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 607373-82-0(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 607373-82-0 differently. You can refer to the following data:
1. 2-Hydroxy-methoxy-5-nitropyridine is used in the preparation of Rho-Kinase inhibitors that display antihypertensive activity. Also it is used in the preparation of aminofurans as potent inhibitors of AKT kinase.
2. 2-Hydroxy-methoxy-5-nitropyridine is used in the preparation of Rho-Kinase inhibitors that display antihypertensive activity. Also it is used in the preparation of aminofurans as potent inhibitors of AKT kinase.

InChI:InChI=1/C6H6N2O4/c1-12-5-2-6(9)7-3-4(5)8(10)11/h2-3H,1H3,(H,7,9)

Upstream product

• 607373-83-1 2-chloro-4-methoxy-5-nitro-pyridine 
• 31872-62-5 4-methoxy-3-nitro-pyridine 

Downstream Products

• 850663-77-3 3-{[2-(4-amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzamide 
• 850663-83-1 methyl 3-{[2-(4-amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate 
• 850663-84-2 3-{[2-(4-amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoic acid 
• 850663-97-7 methyl 3-{[2-(4-amino-furazan-3-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate 
• 850663-82-0 4-(6-bromo-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine 
• 850663-81-9 (6-bromo-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)(hydroxyimino)acetonitrile 
• 850663-98-8 methyl 3-[(4-amino-5-nitro-2-pyridinyl)oxy]benzoate 
• 850663-80-8 (6-bromo-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile 
• 850664-00-5 methyl 3-[(4,5-diamino-2-pyridinyl)oxy]benzoate 
• 850663-78-4 2-bromo-5-nitro-N-phenyl-4-pyridinamine 
• 850663-79-5 6-bromo-N⁴-phenyl-3,4-pyridinediamine 
• 913642-24-7 1,1-dimethylethyl (4-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}butyl)carbamate 
• 913642-35-0 2-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]methyl}-1H-isoindole-1,3(2H)-dione 
• 913642-28-1 1,1-dimethylethyl ((1S)-2-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-1-methylethyl)carbamate 

Relevant articles and documents

PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES

The present invention relates to pyridinyl and pyrazinyl-(aza)indolsulfonamides having GPR17 modulator activity. The compounds have utility in the treatment of a variety of GPR17-associated disorders.

METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF

Methods are disclosed for the preparation of netupitant and pharmaceutically acceptable salts thereof which are novel, easily reproducible, environmentally safe and cost effective. The methods may employ inexpensive starting materials and the preparation processes for intermediates are simple and highly reproducible. Novel intermediates for the preparation of netupitant and pharmaceutically acceptable salts thereof are also disclosed. Amorphous netupitant and methods of making same are disclosed.

Discovery of aminofurazan-azabenzimidazoles as inhibitors of rho-kinase with high kinase selectivity and antihypertensive activity

The discovery, proposed binding mode, and optimization of a novel class of Rho-kinase inhibitors are presented. Appropriate substitution on the 6-position of the azabenzimidazole core provided subnanomolar enzyme potency in vitro while dramatically improving selectivity over a panel of other kinases. Pharmacokinetic data was obtained for the most potent and selective examples and one (6n) has been shown to lower blood pressure in a rat model of hypertension. Despite many available treatments, hypertension remains a prevalent problem. In fact, some 30% of hypertensive patients are unable to reach their blood pressure goals. Thus, a new anti-hypertensive treatment, which acts on a broader patient population, would be an important addition to existing treatments. A number of vasoconstrictive agents, including angiotensin II, endothelin-1, and urotensin-II, exert their effect through RhoA and the downstream kinase Rho-kinase (ROCK1).1 Because of its central role in the control of smooth muscle contraction, inhibition of ROCK1 could lead to a more broadly efficacious anti-hypertensive agent.2 ROCK1 inhibitors have been shown to relax vascular smooth muscle and lower blood pressure in several animal models of hypertension.3 Therefore, we began an effort to identify potent ROCK1 inhibitors with pharmacokinetic profiles consistent with once daily oral dosing.